| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 06/17/2004 | CA2507750A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | CA2505783A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427433A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue |
| 06/16/2004 | EP1427430A2 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427424A2 Lpa receptor agonists and antagonists and methods of use |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
| 06/16/2004 | EP1427379A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1339406B1 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
| 06/16/2004 | EP1187539A4 Method and composition for masking mineral taste |
| 06/16/2004 | EP1100476B1 Formulations for the transdermal administration of fenoldopam |
| 06/16/2004 | EP1027053B1 Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505551A Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
| 06/16/2004 | CN1505517A Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504480A Endothelin receptor antagonist of tripeptide |
| 06/16/2004 | CN1504229A Immune toxin expelling powder for treating chronic kidney degeneration and uremia |
| 06/16/2004 | CN1153764C Substituted benzylaminopiperidine compounds |
| 06/16/2004 | CN1153759C Novel delta-amino-gamma-hydroxy-omega-aryl-alkane amide compounds |
| 06/16/2004 | CN1153588C Dialysis fluid containing peptides as osmotic agents obtained from casein and bicarbonate ions as buffering agents |
| 06/16/2004 | CN1153576C Composition and method for treating bladder cancer |
| 06/15/2004 | US6750360 Lipoxin compounds and their use in treating cell proliferative disorders |
| 06/15/2004 | US6750350 Therapy for sexual disorders |
| 06/15/2004 | US6750228 Uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions |
| 06/15/2004 | US6750226 For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease |
| 06/15/2004 | US6750214 Quinoline and quinazoline compounds useful in therapy |
| 06/15/2004 | US6750202 Inhibitors of procollagen c-proteinase (pcp), for treating fibrosis of the liver |
| 06/15/2004 | US6750026 To diagnose diseases relating to under- or over-expression of hfgan72 receptor ligands; for treatment of obesity, diabetes, anorexia nervosa, bulimia, cachexia, chronic renal failure, congestive heart failure |
| 06/15/2004 | US6749851 Applying radiation |
| 06/15/2004 | CA2159330C Inhibition of leukocyte adhesion |
| 06/15/2004 | CA2153195C New benzopyran derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
| 06/10/2004 | WO2004048401A1 Peptides and medicinal compositions containing the same |
| 06/10/2004 | WO2004048386A2 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS |
| 06/10/2004 | WO2004048375A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 06/10/2004 | WO2004048373A1 Carbamic acid esters with an anticholinergic action |
| 06/10/2004 | WO2004047830A2 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction |
| 06/10/2004 | WO2004047811A1 Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia |
| 06/10/2004 | WO2004030671A3 Use of 4-amino-quinazolines as anti cancer agents |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004000225A3 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003048116A3 Esters and amides as ppar-alpha agonists ____________ |
| 06/10/2004 | WO2003040170A9 Antibodies to cd40 |
| 06/10/2004 | WO2003035049A3 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110840 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/10/2004 | US20040110832 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc |
| 06/10/2004 | US20040110824 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 06/10/2004 | US20040110823 Bone disorders; cardiovascualr disorders; hormone replacement therapy |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110784 Remedies for vesical stimulation association with prostatauxe |
| 06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
| 06/10/2004 | US20040110764 Inhibit oncogene Ras; treating neurofibromin benign proliferative disorder; cancer (combination therapy); blindness, hepatitis infection, restenosis, polycystic kidney disease; imidazo[2,1-b]thiazole derivatives for example |
| 06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110723 Modified psma ligands and uses related thereto |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110709 Genetic modification of the lung as a portal for gene delivery |
| 06/10/2004 | US20040110180 Comprises enzymatic polypeptide for diagnosis, treatment and prevention of cardiovascular, immune system, nervous system, lipid and cell proliferative disorders; drug screening |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109843 Pharmaceutical composition containing decoy and use of the same |
| 06/10/2004 | CA2507616A1 Highly stable pacap/vip-derived peptides |
| 06/10/2004 | CA2507266A1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 06/10/2004 | CA2506310A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 06/10/2004 | CA2502614A1 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
| 06/09/2004 | EP1426355A1 Crystals of hydroxynorephedrine derivative |
| 06/09/2004 | EP1426054A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1425284A2 Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
| 06/09/2004 | EP1425258A2 Hydroxyeicosenoic acid analogs |
| 06/09/2004 | EP1425042A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425030A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 06/09/2004 | EP1425009A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 06/09/2004 | EP1235797B1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 06/09/2004 | EP1000039B1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 06/09/2004 | EP0892786B1 New carboxylic acid derivatives, their production and use |
| 06/09/2004 | CN1503797A Pyridopyrimidine or naphthyridine derivative |
| 06/09/2004 | CN1503792A Phthalazinones derivatives useful as pde 4/7 inhibtors |
| 06/09/2004 | CN1503786A Large conductance calcium-activated k channel opener |